Zacks2d agobearish
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowIn the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
56last 24h
977last 7d
109● bullish (7d)
122● bearish (7d)
212publishers
Zacks45d agobearish
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks60d agobearish
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowIn the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
Simply Wall St.75d agobearish
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices. This index inclusion comes as Recursion’s AI‑native drug discovery platform and recent clinical and data‑driven milestones increasingly draw interest from large investors and collaborators. We’ll now examine how this broader index inclusion, alongside Recursion’s AI‑driven discovery progress,...
Zacks86d agobearish
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to NoteRecursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.